Like many industries, Life Sciences companies continue to be driven by an ever-increasing focus on addressing their customer needs through digital innovation. In a highly competitive landscape and complex regulatory ecosystem, drug and medical device companies require a sustainable competitive advantage, and this can be achieved by adopting disruptive and innovative technologies.
Never have there been so many opportunities to disrupt the status quo through new digital technology, from predictive analytics and data science, to neural machine translation, machine learning and sophisticated artificial intelligence.
This disruption requires a highly collaborative approach among internal cross-functional team members, regulatory agencies and diverse external partners.
During this exclusive breakfast roundtable discussion hosted by Amplexor Life Sciences, dynamic thought leaders will provide valuable insights on the fast pace of advanced technologies in Life Sciences and relevant regulatory implications and considerations. They will also focus on why Life Sciences companies need to be more disruptive in order to provide customers with optimal outcomes and meaningful results.